cholangiocarcinoma

News

Partner's Bizengri is first drug for rare, aggressive cancer

Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.

News

Loudspeaker used by a man, graphic art representation

'Dismal' survival demands change in bile duct cancer therapy

International cancer experts have called for big changes to bile duct cancer, which kills three-quarters of patients within a year of diagnosis.

News

NICE changes its mind on rare bile duct cancer drug from Inc...

Incyte's Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for money.

News

FDA approves Incyte's Pemazyre for rare bile duct cancer

The FDA has approved Incyte's Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile duct.

Partner's Bizengri is first drug for rare, aggressive cancer

'Dismal' survival demands change in bile duct cancer therapy

NICE changes its mind on rare bile duct cancer drug from Inc...

FDA approves Incyte's Pemazyre for rare bile duct cancer

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

cholangiocarcinoma

Editor's Picks